Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627934 | 0.93 | CA12 (0.38) | CA12CA1CA9ALPLMAPT | |
| SCHEMBL628629 | 0.84 | CA12 (0.38) | CA12CA1CA9ALPLMAPT | |
| SCHEMBL20402739 | 0.77 | ALPL (0.35) | ALPLMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL627442 | 0.77 | ALPL (0.49) | ALPLMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15580953 | 0.74 | MAPT (0.32) | CA12CA1CA9MAPTPREP | |
| SCHEMBL6604988 | 0.71 | TTK (0.37) | ALPLMAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2452033 | 0.70 | ALPL (0.43) | ALPLSMN1; SMN2 | |
| SCHEMBL18180085 | 0.70 | CA12 (0.38) | CA12CA1CA9MAPTPREP | |
| SCHEMBL628214 | 0.70 | PDPK1 (0.50) | CA12CA1CA9 | |
| SCHEMBL5255810 | 0.69 | SCN2A (0.65) | CA12CA1CA9PREPSCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028934-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-07-24 | — | — | US | disclosed |
| US-9597317-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-03-21 | — | — | US | disclosed |
| US-20160311776-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-10-27 | — | — | US | disclosed |
| US-20160310465-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-10-27 | — | — | US | disclosed |
| US-9408850-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-08-09 | — | — | US | disclosed |
| US-20140080807-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080807-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | CA12 4803/4885CA1 4593/4885CA9 3640/4885 |
| US-20160310465-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | CA12 4799/4885CA1 4525/4885CA9 3848/4885 |
| US-10028934-B2 | Substituted indazole derivatives active as kinase inhibitiors | MAP3K20, MAP3K1, MAP3K5 | CA12 4799/4885CA1 4525/4885CA9 3848/4885 |
| US-20160311776-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | CA12 4799/4885CA1 4525/4885CA9 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.